Loading news...
Inspire Medical Systems, Inc. (INSP) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Bamco Inc. NY decreased its holdings in shares of Inspire Medical Systems, Inc. (NYSE: INSP) by 61.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 190,023 shares of the company's stock after selling 301,729 shares during the quarter.
Inspire (INSP) reported earnings 30 days ago. What's next for the stock?
I initiate coverage on Inspire Medical Systems (INSP) with a speculative buy, citing its innovation and leadership in hypoglossal nerve stimulation for obstructive sleep apnea. INSP's depressed 1.6x EV/Sales valuation, versus its historical 8–12x range, presents a compelling long-term entry point despite current reimbursement and competitive headwinds. I expect the Inspire V rollout and expanding ambulatory surgery center penetration to drive growth, with CMS reimbursement issues likely to de-risk progressively through 2026.
Inspire Medical continues to grow on strong Q4 results and continued R&D investments as the company advances its sleep apnea therapy.
MINNEAPOLIS, March 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026. Inspire is scheduled to present at 1:30 p.m.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Inspire Medical Systems, Inc. (NYSE: INSP). In August of 2025, contrary to the Company's repeated assurances that it had met all regulatory, technical, and commercial prerequisites for the launch of its Inspire V device, the Company disclosed that the launch faced an "elo.
Inspire Medical Systems, Inc. (NYSE: INSP - Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $68.05, but opened at $63.02. Inspire Medical Systems shares last traded at $62.9650, with a volume of 315,166 shares. Analysts Set New Price Targets A number of brokerages have recently commented
NEW YORK and NEW ORLEANS, Feb. 13, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Inspire Medical Systems faces intensifying competition, reimbursement headwinds, and decelerating growth in the obstructive sleep apnea device market. Despite Q4 revenue and EPS beats, FY26 guidance implies just 4–10% revenue growth, higher capex, and a projected net loss amid operational challenges. Valuation remains stretched even after a 66% stock decline; DCF analysis suggests current pricing bakes in optimistic growth and margin assumptions.
INSP beats Q4 estimates with EPS up 43% and wider margins, but shares tumble 8.7% after a lower 2026 revenue outlook.
Inspire Medical Systems, Inc. (INSP) Q4 2025 Earnings Call Transcript
Inspire Medical Systems (INSP) came out with quarterly earnings of $1.65 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $1.15 per share a year ago.
Fourth quarter revenue growth of 12% and full year revenue growth of 14% Fourth quarter net income per diluted share of $4.66; adjusted net income per diluted share of $1.65 Full year net income per diluted share of $4.89; adjusted net income per diluted share of $2.42 Operating cash flow of $52.5 million in the fourth quarter with full year operating cash flow of $117.0 million MINNEAPOLIS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2025. “We are very excited with the strong finish to 2025.
Evaluate the expected performance of Inspire (INSP) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
New York State Common Retirement Fund trimmed its holdings in Inspire Medical Systems, Inc. (NYSE: INSP) by 73.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,247 shares of the company's stock after selling 141,021 shares during the period. New York State
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Inspire Medical Systems, Inc. (NYSE: INSP). In August of 2025, contrary to the Company's repeated assurances that it had met all regulatory, technical, and commercial prerequisites for the launch of its Inspire V device, the Company disclosed that the launch faced an "elo.